Measuring liver energy use in people with diabetes and fatty liver disease
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes, confirmed by a blood test.
- You are between 18 and 80 years old.
- Your body mass index (BMI) is between 25 and 40.
- Your average blood sugar (HbA1c) is between 7% and 10%.
- You have been diagnosed with moderate to severe fatty liver (with or without some liver scarring).
- You are not taking insulin and have been on metformin for less than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This study looks at how a single session of exercise affects the body's natural sugar production in people with type 2 diabetes and fatty liver. It may help us find better ways to control blood sugar and treat fatty liver.
This study looks at differences in body fat to understand why some people develop type 2 diabetes. You may be asked for blood tests and health information to see if your diabetes risk and body fat patterns are linked.
This study looks at how well a simple blood test (called FIB-4) can measure liver damage (fibrosis) in people with type 2 diabetes. You may join to help find out if this test can help detect liver problems early.
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.